Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10034646 | 1.00 | HTR2C (0.49) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL15217043 | 0.85 | HTR2C (0.47) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL15219155 | 0.82 | HTR2C (0.48) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL21262057 | 0.79 | HTR2C (0.50) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL22578950 | 0.79 | HTR2C (0.50) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL26669784 | 0.75 | PIM1 (0.45) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL15858056 | 0.75 | HTR2C (0.45) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL16422691 | 0.75 | HTR3E (0.50) | HTR2CHTR2A | |
| SCHEMBL18291384 | 0.75 | HTR2C (0.44) | HTR2CHTR2AHTR2BKCNH2PIM1 | |
| SCHEMBL6766547 | 0.74 | HTR2C (0.57) | HTR2CHTR2APIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012033144-A1 | PYRAZOLOQUINOLINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | HTR2C 4031/4885HTR2A 3728/4885HTR2B 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.